Symbols / ABOS Stock $2.43 -2.61% Acumen Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • NMS
ABOS (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Daniel J. O'Connell M.B.A.
Exch · Country NMS · United States
Market Cap 175.15M
Enterprise Value 82.50M
Income -113.28M
Sales —
FCF (ttm) -67.24M
Book/sh 1.21
Cash/sh 1.78
Employees 60
Insider 10d —
IPO Jul 01, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1.58
PEG —
P/S —
P/B 2.00
P/C —
EV/EBITDA -0.72
EV/Sales —
Quick Ratio 4.39
Current Ratio 4.55
Debt/Eq 35.49
LT Debt/Eq —
EPS (ttm) -1.85
EPS next Y -1.54
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-11
Earnings (prior) 2026-05-12
ROA -42.37%
ROE -93.23%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 72.23M
Shs Float 37.01M
Insider Own 6.67%
Instit Own 59.62%
Short Float 3.33%
Short Ratio 4.05
Short Interest 1.68M
52W High 3.60
vs 52W High -32.64%
52W Low 0.97
vs 52W Low 149.74%
Beta —
Impl. Vol. 1.67%
Rel Volume 0.12
Avg Volume 538.72K
Volume 66.12K
Target (mean) $7.40
Tgt Median $8.00
Tgt Low $4.00
Tgt High $10.00
# Analysts 5
Recom None
Prev Close $2.49
Price $2.42
Change -2.61%
About

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$7.40
Mean price target
2. Current target
$2.43
Latest analyst target
3. DCF / Fair value
$-16.76
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.43
Low
$4.00
High
$10.00
Mean
$7.40

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-26 reit BTIG Buy → Buy $8
2026-03-16 main BTIG Buy → Buy $8
2026-01-27 main BTIG Buy → Buy $7
2025-11-18 main B of A Securities Buy → Buy $8
2025-08-25 main B of A Securities Buy → Buy $9
2025-06-17 init Citigroup — → Buy $4
2025-03-28 main UBS Buy → Buy $4
2025-03-28 main HC Wainwright & Co. Buy → Buy $11
2024-11-13 reit HC Wainwright & Co. Buy → Buy $15
2024-10-03 reit HC Wainwright & Co. Buy → Buy $15
2024-08-15 main UBS Buy → Buy $6
2024-08-14 reit HC Wainwright & Co. Buy → Buy $15
2024-07-25 init Citigroup — → Buy $7
2024-05-15 reit HC Wainwright & Co. Buy → Buy $15
2024-03-31 main UBS Buy → Buy $14
2024-03-27 main HC Wainwright & Co. Buy → Buy $15
2023-12-12 init Deutsche Bank — → Buy $8
2023-08-09 reit Credit Suisse Outperform → Outperform $13
2023-08-09 reit HC Wainwright & Co. Buy → Buy $15
2023-07-17 reit Cantor Fitzgerald Overweight → Overweight $13
News
RSS: Latest ABOS news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-16 RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security — 6,060,606 $3.30 $20,000,000
2026-03-06 MEISNER DEREK M Officer — 2,090 $1.85 $3,866
2026-03-06 MEISNER DEREK M Officer — 2,090 $3.26 $6,813
2026-02-27 MEISNER DEREK M Officer — 9,406 $1.85 $17,401
2026-02-27 MEISNER DEREK M Officer — 9,406 $3.01 $28,311
2026-01-28 MEISNER DEREK M Officer — 17,756 $1.85 $32,849
2026-01-28 MEISNER DEREK M Officer — 17,756 $2.08 $39,394
2026-01-23 MEISNER DEREK M Officer — 8,934 $1.81 $16,721
2026-01-22 WILLIAM MATTHEW ZUGA Chief Financial Officer — 4,160 $1.81 $7,607
2026-01-22 O'CONNELL DANIEL JOSEPH Chief Executive Officer — 12,035 $1.81 $21,993
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
123.83
+8.61%
114.02
+86.49%
61.14
+35.15%
45.24
Research And Development
104.89
+11.82%
93.80
+121.65%
42.32
+30.77%
32.36
Selling General And Administration
18.95
-6.29%
20.22
+7.43%
18.82
+46.16%
12.88
General And Administrative Expense
18.95
-6.29%
20.22
+7.43%
18.82
+46.16%
12.88
Other Gand A
18.95
-6.29%
20.22
+7.43%
18.82
+46.16%
12.88
Total Expenses
123.83
+8.61%
114.02
+86.49%
61.14
+35.15%
45.24
Operating Income
-123.83
-8.61%
-114.02
-86.49%
-61.14
-35.15%
-45.24
Total Operating Income As Reported
-123.83
-8.61%
-114.02
-86.49%
-61.14
-35.15%
-45.24
EBITDA
-116.93
-19.21%
-98.08
-90.06%
-51.61
-20.89%
-42.69
Normalized EBITDA
-116.47
-16.85%
-99.67
-98.37%
-50.25
-17.71%
-42.69
Reconciled Depreciation
0.18
+3.37%
0.18
-3.26%
0.18
+8.88%
0.17
EBIT
-117.11
-19.18%
-98.26
-89.73%
-51.79
-20.85%
-42.86
Total Unusual Items
-0.46
-128.93%
1.59
+216.91%
-1.36
—
Total Unusual Items Excluding Goodwill
-0.46
-128.93%
1.59
+216.91%
-1.36
—
Net Income
-121.33
-18.57%
-102.33
-95.39%
-52.37
-22.20%
-42.86
Pretax Income
-121.33
-18.57%
-102.33
-95.39%
-52.37
-22.20%
-42.86
Net Non Operating Interest Income Expense
3.22
-68.55%
10.25
+0.38%
10.21
+326.84%
2.39
Interest Expense Non Operating
4.22
+3.83%
4.07
+600.17%
0.58
0.00
Net Interest Income
3.22
-68.55%
10.25
+0.38%
10.21
+326.84%
2.39
Interest Expense
4.22
+3.83%
4.07
+600.17%
0.58
0.00
Interest Income Non Operating
7.45
-47.98%
14.32
+32.68%
10.79
+351.13%
2.39
Interest Income
7.45
-47.98%
14.32
+32.68%
10.79
+351.13%
2.39
Other Income Expense
-0.73
-150.45%
1.44
+199.72%
-1.44
-13018.18%
-0.01
Other Non Operating Income Expenses
-0.27
-76.16%
-0.15
-81.93%
-0.08
-654.55%
-0.01
Gain On Sale Of Security
-0.46
-128.93%
1.59
+216.91%
-1.36
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-121.33
-18.57%
-102.33
-95.39%
-52.37
-22.20%
-42.86
Net Income From Continuing Operation Net Minority Interest
-121.33
-18.57%
-102.33
-95.39%
-52.37
-22.20%
-42.86
Net Income From Continuing And Discontinued Operation
-121.33
-18.57%
-102.33
-95.39%
-52.37
-22.20%
-42.86
Net Income Continuous Operations
-121.33
-18.57%
-102.33
-95.39%
-52.37
-22.20%
-42.86
Normalized Income
-120.88
-16.32%
-103.92
-103.72%
-51.01
-19.03%
-42.86
Net Income Common Stockholders
-121.33
-18.57%
-102.33
-95.39%
-52.37
-22.20%
-42.86
Diluted EPS
-2.00
-16.96%
-1.71
-58.33%
-1.08
-1.89%
-1.06
Basic EPS
-2.00
-16.96%
-1.71
-58.33%
-1.08
-1.89%
-1.06
Basic Average Shares
60.56
+0.91%
60.01
+23.46%
48.61
+19.72%
40.60
Diluted Average Shares
60.56
+0.91%
60.01
+23.46%
48.61
+19.72%
40.60
Diluted NI Availto Com Stockholders
-121.33
-18.57%
-102.33
-95.39%
-52.37
-22.20%
-42.86
Line Item Trend 2023-12-31
Total Assets
310.12
Current Assets
246.62
Cash Cash Equivalents And Short Term Investments
243.52
Cash And Cash Equivalents
66.89
Other Short Term Investments
176.64
Receivables
0.23
Other Receivables
—
Accrued Interest Receivable
0.23
Prepaid Assets
0.91
Other Current Assets
1.96
Total Non Current Assets
63.51
Net PPE
0.50
Gross PPE
0.50
Other Properties
0.50
Goodwill And Other Intangible Assets
0.17
Other Intangible Assets
0.17
Investments And Advances
62.55
Non Current Prepaid Assets
0.04
Other Non Current Assets
0.24
Total Liabilities Net Minority Interest
43.15
Current Liabilities
12.97
Payables And Accrued Expenses
8.20
Payables
1.38
Accounts Payable
1.38
Current Accrued Expenses
6.82
Employee Benefits
0.00
Pensionand Other Post Retirement Benefit Plans Current
3.69
Current Debt And Capital Lease Obligation
0.87
Current Debt
—
Other Current Borrowings
—
Current Capital Lease Obligation
0.87
Other Current Liabilities
0.21
Total Non Current Liabilities Net Minority Interest
30.18
Long Term Debt And Capital Lease Obligation
27.62
Long Term Debt
27.34
Long Term Capital Lease Obligation
0.28
Preferred Securities Outside Stock Equity
—
Stockholders Equity
266.97
Common Stock Equity
266.97
Capital Stock
0.01
Common Stock
0.01
Preferred Stock
0.00
Share Issued
57.91
Ordinary Shares Number
57.91
Treasury Shares Number
0.00
Additional Paid In Capital
489.45
Retained Earnings
-222.80
Gains Losses Not Affecting Retained Earnings
0.31
Other Equity Adjustments
0.31
Total Equity Gross Minority Interest
266.97
Total Capitalization
294.31
Working Capital
233.64
Invested Capital
294.31
Total Debt
28.49
Capital Lease Obligations
1.15
Net Tangible Assets
266.80
Tangible Book Value
266.80
Available For Sale Securities
62.55
Derivative Product Liabilities
2.56
Interest Payable
0.25
Investmentin Financial Assets
62.55
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-115.54
-34.01%
-86.22
-100.20%
-43.06
-22.50%
-35.15
Cash Flow From Continuing Operating Activities
-115.54
-34.01%
-86.22
-100.20%
-43.06
-22.50%
-35.15
Net Income From Continuing Operations
-121.33
-18.57%
-102.33
-95.39%
-52.37
-22.20%
-42.86
Depreciation Amortization Depletion
0.18
+3.37%
0.18
-3.26%
0.18
+8.88%
0.17
Depreciation
0.18
+3.37%
0.18
-3.26%
0.18
+8.88%
0.17
Depreciation And Amortization
0.18
+3.37%
0.18
-3.26%
0.18
+8.88%
0.17
Other Non Cash Items
1.29
-4.59%
1.35
+52.71%
0.88
—
Stock Based Compensation
9.85
+2.25%
9.63
+56.79%
6.14
+100.75%
3.06
Operating Gains Losses
0.40
+123.77%
-1.69
-225.06%
1.35
—
Gain Loss On Investment Securities
0.40
+123.77%
-1.69
-225.06%
1.35
—
Change In Working Capital
-5.12
-143.93%
11.65
+201.42%
3.87
-3.01%
3.99
Change In Receivables
—
—
—
—
Change In Prepaid Assets
1.36
+137.25%
-3.66
-890.79%
-0.37
-121.71%
1.70
Change In Payables And Accrued Expense
-6.52
-142.74%
15.26
+255.83%
4.29
+67.50%
2.56
Change In Accrued Expense
-1.43
-112.99%
10.99
+141.57%
4.55
+126.54%
2.01
Change In Payable
-5.09
-219.33%
4.27
+1735.63%
-0.26
-147.28%
0.55
Change In Account Payable
-5.09
-219.33%
4.27
+1735.63%
-0.26
-147.28%
0.55
Change In Other Current Assets
0.04
-45.95%
0.07
+205.71%
-0.07
+48.91%
-0.14
Change In Other Current Liabilities
0.00
+100.00%
-0.02
-235.29%
0.02
+112.41%
-0.14
Investing Cash Flow
133.93
+178.87%
48.03
+127.98%
-171.67
-538.10%
39.19
Cash Flow From Continuing Investing Activities
133.93
+178.87%
48.03
+127.98%
-171.67
-538.10%
39.19
Net PPE Purchase And Sale
-0.09
-450.00%
-0.02
+11.11%
-0.02
+88.82%
-0.16
Purchase Of PPE
-0.09
-450.00%
-0.02
+23.81%
-0.02
+86.96%
-0.16
Sale Of PPE
—
0.00
-100.00%
0.00
0.00
Capital Expenditure
-0.09
-450.00%
-0.02
+23.81%
-0.02
+86.96%
-0.16
Net Investment Purchase And Sale
134.02
+178.96%
48.04
+127.99%
-171.65
-536.27%
39.35
Purchase Of Investment
-38.06
+77.71%
-170.73
+31.88%
-250.63
-503.73%
-41.51
Sale Of Investment
172.08
-21.34%
218.77
+177.00%
78.98
-2.32%
80.86
Financing Cash Flow
-0.03
-100.49%
6.93
-95.43%
151.75
+3784.13%
3.91
Cash Flow From Continuing Financing Activities
-0.03
-100.49%
6.93
-95.43%
151.75
+3784.13%
3.91
Net Issuance Payments Of Debt
0.00
+100.00%
-0.74
-102.46%
30.00
0.00
Issuance Of Debt
—
0.00
-100.00%
30.00
0.00
Repayment Of Debt
0.00
+100.00%
-0.74
0.00
—
Long Term Debt Issuance
—
0.00
-100.00%
30.00
0.00
Long Term Debt Payments
0.00
+100.00%
-0.74
0.00
—
Net Long Term Debt Issuance
0.00
+100.00%
-0.74
-102.46%
30.00
0.00
Net Common Stock Issuance
-0.07
-100.92%
7.90
-93.52%
121.90
+3114.77%
3.79
Common Stock Payments
-0.07
-78.05%
-0.04
0.00
—
Cash Dividends Paid
—
0.00
0.00
—
Repurchase Of Capital Stock
-0.07
-78.05%
-0.04
0.00
—
Proceeds From Stock Option Exercised
0.04
0.00
-100.00%
0.33
+182.61%
0.12
Net Other Financing Charges
—
-0.23
+51.68%
-0.48
—
Changes In Cash
18.36
+158.74%
-31.26
+50.37%
-62.98
-893.32%
7.94
Beginning Cash Position
35.86
-46.57%
67.12
-48.41%
130.10
+6.50%
122.16
End Cash Position
54.22
+51.20%
35.86
-46.57%
67.12
-48.41%
130.10
Free Cash Flow
-115.63
-34.09%
-86.23
-100.14%
-43.09
-22.01%
-35.31
Interest Paid Supplemental Data
2.94
-1.24%
2.97
+1659.17%
0.17
0.00
Income Tax Paid Supplemental Data
0.00
0.00
0.00
0.00
Amortization Of Securities
-0.81
+83.87%
-5.01
-60.69%
-3.12
-740.86%
0.49
Common Stock Issuance
0.00
-100.00%
7.94
-93.49%
121.90
+3114.77%
3.79
Interest Paid CFF
—
0.00
+100.00%
-0.48
—
Issuance Of Capital Stock
0.00
-100.00%
7.94
-93.49%
121.90
+3114.77%
3.79
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category